(fla-vo-cox-id) ,


(trade name)


Therapeutic: nonopioid analgesics
Pharmacologic: flavanoids
Pregnancy Category: UK


Dietary management of osteoarthritis; considered to be a medical food product.


Anti-inflammatory and analgesic properties related to inhibition of prostaglandin synthesis by inhibiting cyclo-oxygenase (not COX-2 selective) and other mediators of inflammation.

Therapeutic effects

Decreased pain/inflammation associated with osteoarthritis, with improved mobility.


Absorption: Some intestinal conversion prior to absorption, remainder unknown.
Distribution: Unknown.
Metabolism and Excretion: Mostly metabolized by the liver.
Half-life: Unknown.

Time/action profile (analgesic effect)

POwithin 1–2 hrunknown12 hr


Contraindicated in: Hypersensitivity; Obstetric / Lactation / Pediatric: Not recommended.
Use Cautiously in: History of GI bleeding.

Adverse Reactions/Side Effects


  • ↑ BP
  • ↑ in varicose veins


  • GI upset


  • psoriasis


Drug-Drug interaction

None noted.


Oral (Adults) 250 mg every 12 hr (up to 250 mg three times daily has been used).


Capsules: 250 mg

Nursing implications

Nursing assessment

  • Assess pain (note type, location, and intensity), range of motion, degree of swelling, and stiffness in affected joints before and periodically during therapy.

Potential Nursing Diagnoses

Chronic pain (Indications)


  • Oral: Administer flavocoxid twice daily.

Patient/Family Teaching

  • Instruct patient to take flavocoxid as directed. Do not increase does without consulting health care professional.

Evaluation/Desired Outcomes

  • Decrease in pain and stiffness, and improved mobility in patients with osteoarthritis.


an oral nutritional supplement.
indication This drug is used for dietary management of osteoarthritis.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects Adverse effects of this drug include hypertension, increase in varicose veins, psoriasis, and fluid accumulation in the knees.
Mentioned in ?
References in periodicals archive ?
A proprietary mixture of flavonoids (baicalin and catechin), known as flavocoxid (Limbrel) was tested against naproxen, a conventional nonsteroidal anti-inflammatory drug for the management of moderate osteoarthritis of the knees.
Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages.
Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis.
Flavocoxid is marketed as a medical food for the management of OA.
Now along comes Limbrel, each capsule containing 250 mg of flavocoxid.
Limbrel contains flavocoxid, a proprietary composition of natural flavonoid ingredients from the plant sources of Scutellaria baicalensis and Acacia catechu that meet the FDA strict safety standard of Generally Recognized As Safe (GRAS).
One such extract with strong supporting human outcome studies, flavocoxid, will be discussed in this article with emphasis on its safety profile and balanced action across a multitude of inflammatory pathways.
Flavocoxid is comprised primarily of flavonoids, such as baicalin and catechin, and Limbrel provides levels of these flavonoids to meet the distinctive nutritional requirements of people with OA and cannot be obtained through simply changing the diet.
Safety, efficacy and acceptability of flavocoxid (Limbrel[TM]) compared with naproxen in subjects with osteoarthritis of the knee: a pilot study.
A proprietary mixture of flavonoids (baicalin and catechin) known as flavocoxid (Limbrel) was tested against naproxen, a conventional non-steroidal anti-inflammatory drug for the management of moderate osteoarthritis (OA) of the knees.
It contains flavocoxid, a patent-pending combination of natural ingredients comprised primarily of concentrated flavonoids baicalin and catechin.